BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7644349)

  • 1. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
    Giarratana MC; Gorin NC; Douay L
    Nouv Rev Fr Hematol (1978); 1995; 37(2):125-30. PubMed ID: 7644349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
    Douay L; Mary JY; Giarratana MC; Najman A; Gorin NC
    Exp Hematol; 1989 Jun; 17(5):429-32. PubMed ID: 2653856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
    Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
    Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
    Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
    Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal blast colony formation: an in vitro tool for monitoring human bone marrow 'purging'.
    Degliantoni G; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1986 Dec; 1(2):209-13. PubMed ID: 3332133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
    Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
    Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
    Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
    Martin H; Bruecher J; Claudé R; Hoelzer D
    Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of human CFU-GM to mafosfamide: analysis of the factors affecting individual variations.
    Domenech J; Desbois I; Linassier C; Gihana E; Chenault S; Brémond JL; Colombat P; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1993 Jun; 11(6):425-31. PubMed ID: 8334422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
    Lopez M; Mary JY; Sainteny F
    Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
    Douay L; Hu C; Giarratana MC; Gorin NC
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging.
    Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D
    Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant.
    Selleri C; Maciejewski JP; De Rosa G; Raiola A; Risitano AM; Picardi M; Pezzullo L; Luciano L; Ricci P; Varriale G; Della Cioppa P; Del Vecchio L; Rotoli B
    Bone Marrow Transplant; 1999 May; 23(10):1029-37. PubMed ID: 10373069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
    Tamayo E; Hervé P
    Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.